

Konstantin Nikolaev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9384402/publications.pdf>

Version: 2024-02-01

105
papers

21,718
citations

50276

46
h-index

37204

96
g-index

112
all docs

112
docs citations

112
times ranked

19082
citing authors

#	ARTICLE	IF	CITATIONS
1	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	27.0	4,215
2	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 323-334.	27.0	2,809
3	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1327-1335.	27.0	2,261
4	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	27.0	2,211
5	Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1489-1499.	27.0	1,838
6	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet</i> , The, 2015, 385, 2067-2076.	13.7	659
7	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	27.0	510
8	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, 534-544.	27.0	379
9	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 119-129.	1.6	347
10	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017, 376, 1517-1526.	27.0	307
11	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	2.8	296
12	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	2.2	222
13	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 374, 1092-1094.	27.0	208
14	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 618-628.	11.4	207
15	Edoxaban versus enoxaparin versus warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. <i>Lancet</i> , The, 2016, 388, 1995-2003.	13.7	206
16	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	2.9	205
17	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	27.0	205
18	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. <i>European Heart Journal</i> , 2018, 39, 363-370.	2.2	199

#	ARTICLE	IF	CITATIONS
19	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal, 2018, 206, 11-23.	2.7	171
20	Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study. European Heart Journal, 2015, 36, 2510-2519.	2.2	169
21	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 2017, 194, 132-140.	2.7	161
22	Alirocumab in Patients With Polyvascular Disease and Recent Acute CoronaryÂSyndrome. Journal of the American College of Cardiology, 2019, 74, 1167-1176.	2.8	154
23	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. Journal of the American Society of Nephrology: JASN, 2018, 29, 2755-2769.	6.1	148
24	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	139
25	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation, 2017, 135, 1273-1275.	1.6	133
26	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology, 2019, 73, 387-396.	2.8	131
27	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. American Journal of Nephrology, 2019, 50, 345-356.	3.1	127
28	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE, 2016, 11, e0164076.	2.5	118
29	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke, 2017, 48, 1218-1225.	2.0	112
30	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. American Journal of Nephrology, 2019, 50, 333-344.	3.1	112
31	Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Diseaseâ€• Results From EMPA-REG OUTCOME<sup>Â</sup>; â€•. Circulation Journal, 2017, 81, 227-234.	1.6	110
32	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation, 2019, 140, 103-112.	1.6	107
33	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open, 2017, 7, e017157.	1.9	92
34	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. Stroke, 2016, 47, 2075-2082.	2.0	83
35	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation, 2019, 140, 2054-2062.	1.6	83
36	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE, 2018, 13, e0191592.	2.5	80

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. Age and Ageing, 2019, 48, 859-866.	1.6	79
38	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S12-20.	2.2	74
39	Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. International Journal of Cardiology, 2016, 223, 543-547.	1.7	71
40	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. Circulation, 2017, 135, 648-655.	1.6	61
41	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. Circulation, 2019, 139, 787-798.	1.6	60
42	Cardioversion of Atrial Fibrillation in <sc>ENGAGE AFâ€TIMI</sc> 48. Clinical Cardiology, 2016, 39, 345-346.	1.8	53
43	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: <sc>T</sc>he <sc>EXAMINE</sc> trial. Diabetes, Obesity and Metabolism, 2017, 19, 664-671.	4.4	53
44	Empagliflozin in women with type 2 diabetes and cardiovascular disease â€“ an analysis of EMPA-REG OUTCOME®. Diabetologia, 2018, 61, 1522-1527.	6.3	49
45	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the American College of Cardiology, 2019, 74, 1177-1186.	2.8	49
46	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Journal, 2017, 185, 93-100.	2.7	48
47	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. Stroke, 2014, 45, 2372-2378.	2.0	46
48	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal, 2019, 40, 2801-2809.	2.2	45
49	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal, 2019, 213, 35-46.	2.7	45
50	Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Journal of Clinical Lipidology, 2018, 12, 958-965.	1.5	44
51	Management and 1â€Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	3.7	44
52	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. European Journal of Heart Failure, 2019, 21, 1571-1579.	7.1	44
53	Comparison of Fatal or Irreversible Events With Extendedâ€Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Journal of the American Heart Association, 2017, 6, .	3.7	40
54	Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 71, 364-367.	2.8	35

#	ARTICLE	IF	CITATIONS
55	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
56	Impact of gender on event rates at 1-year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017, 7, e014579.	1.9	30
57	Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2780-2782.	2.8	30
58	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	2.2	28
59	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. <i>American Heart Journal</i> , 2015, 170, 1140-1150.	2.7	26
60	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 526.	6.1	26
61	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016, 68, 606-613.	2.7	21
62	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	21
63	Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. <i>American Journal of Medicine</i> , 2018, 131, 813-819.e5.	1.5	17
64	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005858.	2.2	17
65	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.5	16
66	Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry. <i>Clinical Cardiology</i> , 2019, 42, 553-560.	1.8	16
67	Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. <i>Acta Cardiologica</i> , 2019, 74, 309-318.	0.9	16
68	Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018, 4, 27-35.	4.0	15
69	CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume10, 107-114.	0.7	14
70	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. <i>British Journal of Haematology</i> , 2016, 174, 610-623.	2.5	13
71	Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan: Insights From GARFIELD-AF. <i>Circulation Journal</i> , 2018, 83, 67-74.	1.6	12
72	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 382-391.	1.6	12

#	ARTICLE	IF	CITATIONS
73	Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry. <i>International Journal of Stroke</i> , 2020, 15, 308-317.	5.9	12
74	Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetes—Prespecified Analyses of ODYSSEY OUTCOMES. <i>Diabetes</i> , 2018, 67, .	0.6	12
75	Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 749-757.	1.6	11
76	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019, 132, 1431-1440.e7.	1.5	8
77	Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. <i>American Heart Journal</i> , 2016, 175, 18-27.	2.7	6
78	The Frequency of the Minor Polymorphisms in the <i>CYP2C19</i> , <i>VEGFR-2</i> Genes, and Clinical Outcomes in Russian and Buryat Patients with Acute Coronary Syndrome. <i>Genetic Testing and Molecular Biomarkers</i> , 2020, 24, 338-342.	0.7	6
79	Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES. <i>Journal of the American College of Cardiology</i> , 2020, 75, 448-451.	2.8	6
80	THE INFLUENCE OF PSYCHOSOCIAL FACTORS ON THE DEVELOPMENT OF ISCHEMIC HEART DISEASE AND ACUTE CORONARY SYNDROME. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2016, 15, 58-62.	1.4	5
81	USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA. <i>Journal of the American College of Cardiology</i> , 2017, 69, 153.	2.8	2
82	Effects of smoking on the level of sp-a and sp-d surfactant proteins in the blood of patients without bronchopulmonary diseases. <i>Bulletin of Siberian Medicine</i> , 2020, 19, 104-111.	0.3	2
83	Estimation of metformin and other sugar reducing therapy influence on the outcomes in patients with acute coronary syndrome and diabetes mellitus type II. <i>Complex Issues of Cardiovascular Diseases</i> , 2021, 10, 39-47.	0.5	2
84	Human chemical status and endothelial function. <i>Journal of Surface Investigation</i> , 2011, 5, 1098-1101.	0.5	1
85	The use of a new semi-quantitative rapid test for procalcitonin in the diagnosis of multisegmental community-acquired pneumonia. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 279-282.	0.8	1
86	Peculiarities of hypoglycaemic therapy in acute coronary syndrome in patients with type 2 diabetes mellitus. <i>Patologiya Krovoobrashcheniya I Kardiokhirurgiya</i> , 2021, 25, 27.	0.2	1
87	Association of cardiovascular biomarkers with myocardial and coronary imaging characteristics in patients having acute myocardial infarction and type 2 diabetes mellitus. <i>Complex Issues of Cardiovascular Diseases</i> , 2021, 10, 104-106.	0.5	1
88	REGIONAL ASPECTS OF THE GENE POLYMORPHISM V β -GFR2 WITH CORONARY ATHEROSCLEROSIS IN ACUTE CORONARY SYNDROME. <i>Russian Journal of Cardiology</i> , 2017, , 61-65.	1.4	1
89	Regional aspects of associations of the CYP2C19 gene polymorphism with coronary atherosclerosis in acute coronary syndrome. <i>Russian Journal of Cardiology</i> , 2018, , 28-32.	1.4	1
90	Association between genetic determinants of clopidogel metabolism and clinical cardiovascular risk indicators in Buryat patients. <i>Patologiya Krovoobrashcheniya I Kardiokhirurgiya</i> , 2019, 23, 39.	0.2	1

#	ARTICLE	IF	CITATIONS
91	Association of SP-A and SP-D Surfactant Proteins with the Severity of CommunityAcquired Pneumonia. Sklifosovsky Journal Emergency Medical Care, 2020, 9, 348-355.	0.6	1
92	ANGIOTENSIN CONVERTING ENZYME INHIBITORS: DECREASE IN HEART REMODELING AND IMPROVEMENT IN FUNCTION OF ENDOTHELIUM IN PATIENTS WITH ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology, 2006, 2, 12-17.	0.8	0
93	521 RAPID AND EFFICIENT IMMUNOCHROMATOGRAPHIC FATTY ACID BINDING PROTEIN ASSAY FOR EARLY DIAGNOSIS OF MYOCARDIAL INFARCTION. Atherosclerosis Supplements, 2011, 12, 111.	1.2	0
94	EARLY MORTALITY IN PATIENTS WITH NEW ONSET ATRIAL FIBRILLATION: RESULTS FROM THE GARFIELD-AF REGISTRY. Journal of the American College of Cardiology, 2017, 69, 315.	2.8	0
95	TREATMENT AND OUTCOMES OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION ACCORDING TO GUIDELINE-DEFINED ANTICOAGULATION THRESHOLDS: RESULTS FROM THE GARFIELD-AF REGISTRY. Journal of the American College of Cardiology, 2017, 69, 364.	2.8	0
96	Associations of psychosocial risk factors and clinical characteristics of acute coronary syndrome in the patients with target values of LDL-C living in the North. Atherosclerosis, 2017, 263, e176.	0.8	0
97	POST-ACUTE CORONARY SYNDROME PATIENTS WITH POLYVASCULAR DISEASE DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: ODYSSEY OUTCOMES. Journal of the American College of Cardiology, 2019, 73, 2034.	2.8	0
98	Associations of functional and biochemical parameters of endothelial dysfunction in postmenopausal women with a different state of carbohydrate metabolism. Diabetes Mellitus, 2015, 18, 105-112.	1.9	0
99	THE PROTOCOL: INFLUENCE OF THE COMBINATION CARRIAGE Ɖ;ƉŁƉ2Ɖ;19*2 AND *17 ON EFFICACY OF CLOPIDOGREL. Russian Journal of Cardiology, 2017, , 113-117.	1.4	0
100	PROTEIN MARKERS OF CARDIONECROSIS IN THE DYNAMICS OF ACUTE CORONARY SYNDROME. The Siberian Scientific Medical Journal, 2018, , .	0.3	0
101	NEW ASPECTS OF THE USE OF PROTEIN TISSUE-SPECIFIC MARKERS IN THE ESTIMATION OF SEVERITY OF COMMUNITY-ACQUIRED PNEUMONIA. The Siberian Scientific Medical Journal, 2019, , .	0.3	0
102	Possibilities of atorvastatin loading dose using for the prevention of perioperative myocardial damage in patients with stable coronary artery disease. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 23-26.	1.4	0
103	PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2484.	1.4	0
104	Evaluation of Clinical Efficiency of Cardioprotective Therapy in Patients with Acute Myocardial Infarction. Sklifosovsky Journal Emergency Medical Care, 2021, 10, 493-503.	0.6	0
105	The Impact of Hypoglycemic Therapy on the Prognosis for Acute Coronary Syndrome in Patients with Type 2 Diabetes. Journal of Personalized Medicine, 2022, 12, 845.	2.5	0